xCures and mProbe partner to help cancer patients determine optimal treatments
xCures partners with mProbe, to leverage their targeted proteomics platform for profiling individual patients’ cancer tissues for actionable drug targets xCures, Inc. is proud to announce their collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to transform the diagnosis, prevention, and […]
xCures and Oblato announce the launch of a Compassionate Use program for OKN-007
Oblato’s first-in-class small molecular OKN-007 will be available through a newly opened compassionate use protocol. xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of […]
Pancreatic Cancer Patients Will Now Have Remote Access to Precision Nutrition Trial Through New Partnership
xCures and Vault Health integration creates a decentralized platform to benefit pancreatic cancer research and facilitate enrollment in Faeth’s NEAAR-001 study xCures, Inc. is proud to partner with Vault Health, a decentralized research and workforce screening company, to facilitate the enrollment of pancreatic cancer patients in Faeth Therapeutics’ NEAAR-001 research study. NEAAR-001 is a clinical trial […]
xCures partners with Travera to support advanced carcinoma patients and their physicians
Decentralized clinical trial for patients with advanced carcinomas helps determine their cancer’s response to specific drugs [EIN Presswire, July 19, 2022] xCures, Inc. is proud to announce their partnership with Travera, and the launch of a decentralized clinical trial that provides patients with advanced carcinoma a functional profile of their cancer cells. Advanced carcinoma patients […]
xCures and Novocure® partner to better understand quality of life in glioblastoma
Innovative collaboration focused on developing the first comprehensive Quality of Life dataset for glioblastoma patients [EIN PressWire June 21, 2022] xCures, Inc., is proud to announce their partnership with Novocure with the intent to develop the first comprehensive, longitudinal Quality of Life (QoL) dataset for glioblastoma (GBM) patients. The alliance between both oncology companies will […]
Prognos Health and xCures Partner to enable Access to Real World Oncology Datasets
The new collaboration focuses on improving outcomes by continuous learning from every patient’s journey across diverse datasets CHICAGO, IL, UNITED STATES, June 3, 2022 /EINPresswire/ Today, at the annual meeting of the American Society of Clinical Oncology (ASCO), Prognos Health and xCures announced a collaboration to enable real-world data access and insights for life science […]
xCures joins C-Path’s Cure Drug Repurposing Collaboratory to Deliver AI-enabled Data Abstraction of Health Records
Members of CDRC will be able to utilize xCures’ technology to quickly abstract and structure clinical data to support drug repurposing studies in rare cancer. xCures today announced has joined the Critical Path Institute’s (C-Path) Cure Drug Repurposing Collaboratory (CDRC). CRDC is operated by C-Path as a public-private partnership with the U.S. Food and Drug […]
Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)
xCures to use tumor sequencing information and its platform to pair patients with available treatment options Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, and xCures, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence, today announced a partnership that […]
xCures announces real world biomarker study for patients with FGFR-mutant bladder cancer receiving Balversa®
Tyra Biosciences supported study investigates if non-invasive blood and urine samples provide biomarkers to assess clinical response to erdafitinib treatment Today, xCures announced their collaboration with Tyra Biosciences for a real-world biomarker study involving patients with FGFR-mutant bladder cancer receiving Balversa® (erdafitinib) as their standard of care medical therapy. The study is supported by Tyra […]